Pathos AI
CHICAGO, IL · Biotechnology · 12 employees
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies. Pathos has raised over $100 million to accelerate the development of precision medicines and to expand its platform, combining computational approaches across multimodal real-world da
Funding history
- Venture - Series Unknown — $283.0M — May 2025
- Venture - Series Unknown — $62.0M — Nov 2024
- Series C — $62.0M — Oct 2024
- Venture - Series Unknown — $20.0M — Mar 2023
Recent signals
- May 01, 2025: Raised $283.0M in Venture - Series Unknown
- Nov 06, 2024: Raised $62.0M in Venture - Series Unknown
- Oct 29, 2024: Raised $62.0M in Series C
- Mar 02, 2023: Raised $20.0M in Venture - Series Unknown
See plans & pricing → Track Pathos AI’s funding, hiring, and signals — with verified contacts — on Fundz.